S.916 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018115th Congress (2017-2018) |
|Sponsor:||Sen. Cassidy, Bill [R-LA] (Introduced 04/24/2017)|
|Committees:||Senate - Health, Education, Labor, and Pensions|
|Latest Action:||House - 05/25/2018 Held at the desk. (All Actions)|
This bill has the status Passed Senate
Here are the steps for Status of Legislation:
- Passed Senate
- Passed House
- To President
- Became Law
Summary: S.916 — 115th Congress (2017-2018)All Information (Except Text)
Reported to Senate with amendment(s) (05/01/2017)
Protecting Patient Access to Emergency Medications Act of 2017
(Sec. 2) This bill amends the Controlled Substances Act to direct the Drug Enforcement Administration (DEA) to register an emergency medical services (EMS) agency to administer controlled substances if the agency submits an application demonstrating that it is authorized to conduct such activity in the state in which the agency practices. The DEA may deny an application if it determines that the registration is inconsistent with the public interest.
An EMS agency may obtain a single registration in each state instead of a separate registration for each location.
A registered EMS agency may deliver, store, and receive controlled substances, subject to specified conditions.
An EMS professional of a registered EMS agency may administer controlled substances in schedules II, III, IV, or V outside the physical presence of a medical director if such administration is authorized under state law and pursuant to a standing or verbal order, subject to specified conditions.
The bill specifies that a hospital-based EMS agency (i.e., an EMS agency owned or operated by a hospital) may continue to administer controlled substances under the hospital's DEA registration.
(Sec. 3) A pharmacy may deliver a controlled substance to an administering practitioner in accordance with this bill's requirements, subject to specified conditions.
The Government Accountability Office must report to Congress on access to and the potential diversion of controlled substances administered by injection, implantation, or through the use of an intrathecal pump.